Ngm Biopharmaceuticals Intrinsic Value Calculation – Column Group Increases Stake in NGM Biopharmaceuticals with Purchase of 22K Shares

November 21, 2023

☀️Trending News

Column Group, a 10% owner of NGM ($NASDAQ:NGM) Biopharmaceuticals, has recently announced that it has acquired more than 22,000 shares of the company. This purchase further increases Column Group’s stake in NGM Biopharmaceuticals. NGM Biopharmaceuticals is a biotechnology company specializing in the discovery, development, and commercialization of novel therapeutics for diseases with unmet medical needs. The company focuses on developing treatments for metabolic, liver, and ophthalmology conditions.

NGM Biopharmaceuticals has promising product candidates in its pipeline, including a Phase 2 clinical trial for treatment of Nonalcoholic steatohepatitis (NASH). This purchase further emphasizes Column Group’s commitment to the success of NGM Biopharmaceuticals.

Market Price

On Monday, NGM BIOPHARMACEUTICALS opened its trading day at $0.7 and closed at $0.6, up by 4.4% from the previous closing price. This increase was driven by news that Column Group had increased its stake in the company, purchasing an additional 22,000 shares. This news is seen as a vote of confidence in the potential of the company’s platform and portfolio of programs. NGM BIOPHARMACEUTICALS will be looking to capitalize on this new investment to continue driving progress in its therapeutic programs and development pipeline. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Ngm Biopharmaceuticals. More…

    Total Revenues Net Income Net Margin
    22.43 -151.14 -673.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Ngm Biopharmaceuticals. More…

    Operations Investing Financing
    -139.64 88.78 2.39
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Ngm Biopharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    192.15 22.34 2.05
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Ngm Biopharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -39.0% -713.7%
    FCF Margin ROE ROA
    -629.2% -55.3% -52.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Ngm Biopharmaceuticals Intrinsic Value Calculation

    At GoodWhale, we recently completed a financial analysis of NGM BIOPHARMACEUTICALS. Our proprietary Valuation Line determined that the intrinsic value of each NGM BIOPHARMACEUTICALS share was around $6.8. This means that the current trading price of $0.6 per share is undervalued by a staggering 91.2%. With such a large discrepancy between the value of the stock and its market price, investors should take note and consider adding NGM BIOPHARMACEUTICALS to their portfolio. More…

  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company discovers and develops next-generation medicines for the treatment of serious diseases. Its product candidates include NGM282, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis; NGM355, which is in Phase I/II clinical trials for the treatment of cholestatic liver diseases; and NGM120, which is in Phase I/II clinical trials for cancer. The company has collaborations with Merck Sharp & Dohme Corp., Sanofi, Alexion Pharmaceuticals, Inc., and Pfizer Inc. NGM Biopharmaceuticals Inc. was founded in 2007 and is headquartered in South San Francisco, California. NGM Biopharmaceuticals Inc’s main competitors are Provention Bio Inc, Axsome Therapeutics Inc, Aileron Therapeutics Inc. All three companies are clinical-stage biopharmaceutical companies that focus on the discovery and development of next-generation medicines for the treatment of serious diseases.

    – Provention Bio Inc ($NASDAQ:PRVB)

    Prevention Bio Inc is a clinical stage biopharmaceutical company developing products to prevent and treat serious infections. The company has a market cap of 722.81M as of 2022 and a Return on Equity of -63.25%. Prevention Bio Inc’s products are based on its proprietary platform technology, which is designed to target and kill pathogenic bacteria, viruses and fungi. The company’s lead product candidate is PREV-001, a prophylactic vaccine for the prevention of Clostridium difficile infection. Prevention Bio Inc is headquartered in San Diego, California.

    – Axsome Therapeutics Inc ($NASDAQ:AXSM)

    Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in developing novel therapies for the management of central nervous system (CNS) disorders. The company’s product pipeline includes treatments for Alzheimer’s disease, migraine, and depression. As of 2022, Axsome’s market cap is $2.56 billion and its ROE is -110.46%.

    Axsome’s negative ROE is due to the fact that the company is not yet profitable. In 2020, Axsome reported a net loss of $103.8 million. The company’s clinical-stage product pipeline and large market potential make it a risky investment, but one with potential high rewards.

    – Aileron Therapeutics Inc ($NASDAQ:ALRN)

    Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on the development of drugs to treat cancer and other diseases. The company’s market cap is $305.62M and its ROE is -56.6%. Aileron’s main product candidate is ALRN-6924, which is in clinical trials for the treatment of solid tumors.


    Investing in NGM Biopharmaceuticals can be a profitable venture. Recently, Column Group, a 10% owner of the company, disclosed their purchase of more than 22,000 shares. This news sent the stock price up the same day, suggesting that investors have confidence in the company’s future prospects. Analysts suggest that investors understand the growth potential of the company’s drugs.

    The company’s pipeline for new products is promising, and their current portfolio of drugs positions them to benefit from recent advances in medicine. As more information becomes available, investors can gain insight into the company’s performance and potential. With a focus on risk management and long-term investments, NGM Biopharmaceuticals provides investors with opportunities for profits in the biopharmaceutical industry.

    Recent Posts

    Leave a Comment